Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

11 February 2020

WHO adviser says an antimicrobial fund can help a market that ‘needs to be fixed’

Following the publication of the 2020 AMR Benchmark and the WHO report on the overall lack of investment in antibiotic development, Ed Silverman of STAT news speaks to Peter Beyer, of the WHO antimicrobial resistance division. The interview is centered around a new investment fund to finance new antimicrobials.

Direct links

Read the full interview

The WHO has been working for the past few months with the European Investment Bank to create an investment fund with up to $1 billion to finance antimicrobials that have new mechanisms of action. STAT news speaks with Peter about the progress. 

The conversation follows the recent publication of the AMR Benchmark in January 2020, which echoes a warning from the World Health Organization that a lack of private investment and innovation in the development of new antibiotics is undermining efforts to combat drug-resistant infections. 

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved